Indeed, increasing evidence has shown that STAT3 is constitutively activated in 82% of prostate cancers, 70% of breast cancers, over 90% of head and neck cancers, and more than 50% of lung cancers [13,14,15,16]. Here, STAT3 is linked to breast carcinoma.